[Clinical evaluation of BRMs in gastric cancer patients].
The concept of BRM includes both immunotherapeutic agents and cytokines. We have tested the effects of various kinds of immunopotentiators on gastric cancer patients in terms of (1) the effects on postoperative survival, (2) the effects on tumor size and (3) immunological effects. The results obtained showed that immunopotentiators produced favorable effects. Cytokines should also be evaluated from the same standpoints as those for immunopotentiators.
Ochiai
T
T
2nd Dept. of Surgery, School of Medicine, Chiba University.
Isono
K
K
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D017358:Cell Wall Skeleton; D006801:Humans; D007912:Lentinan / Q000627:therapeutic use; D009088:Mucoproteins / Q000627:therapeutic use; D009171:Mycolic Acids / Q000627:therapeutic use; D010844:Picibanil / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000401:mortality / Q000628:therapy*
D000276:Adjuvants, Immunologic; D017358:Cell Wall Skeleton; D009088:Mucoproteins; D009171:Mycolic Acids; D007912:Lentinan; D010844:Picibanil